Ultraceuticals
Pipeline & Research Insights

Active Therapeutic Programs & Combinatorial Insights

Ultraceuticals develops proprietary programs while actively co-developing assets with global biotechnology, clinical pharmacology, and academic research partners.

Therapeutic Portfolio

Active Biopharmaceutical
Pipeline & Co-Development

Translating in silico precision into clinical assets. Our internal programs and partner collaborations targeting high-unmet-need indications.

ULTR-ALS-01CHIT1 (Human Chitinase-1)

Amyotrophic Lateral Sclerosis (ALS)

Robust neuroprotective phenotype observed in TDP-43 models

Small Molecule / Microglial Repolarizer
ReviveAI (SCALEX)
ACTIVE
Current Stage:Preclinical In Vivo Validation
ULTR-FILM-06Bacterial EPS Matrix Disrupter

Resistant Microbial Biofilms / P. aeruginosa

100x antibiotic resensitization in cystic fibrosis models

Peptide-Small Molecule Hybrid
BioFilm Omni™ 6.0
ACTIVE
Current Stage:Preclinical Lead Synergy
ULTR-FORM-204Thermally Labile Oncology API

Solid Tumors / High-Dose Bioavailability

Zero degradation after 12-month ICH accelerated testing

Co-Crystalline Solid Dispersion
Enformis™
ACTIVE
Current Stage:IND Formulation Scale-Up
ULTR-ONC-14Mutant Receptor Tyrosine Kinase

Refractory NSCLC & Glioblastoma

Sub-nanomolar selectivity over wild-type kinase

De Novo Allosteric Inhibitor
DiscoveraAI™ Generative
ACTIVE
Current Stage:Lead Optimization
ULTR-MET-88Fibroblast Growth & AMPK Axis

Metabolic Dysfunction / MASH (NASH)

Significant reduction in hepatic fibrosis score

Oral Repurposed Dual Agonist
ReviveAI (SCALEX)
ACTIVE
Current Stage:Preclinical In Vivo
Inquire about co-development licensing & clinical asset partnerships

Program Dossiers & Scientific Profiles

Empirical milestones, biological targets, and licensing data for active internal initiatives.

ULTR-NEURO-01Target: Human Chitinase-1 (CHIT1), TDP-43 & Tau Aggregation
Preclinical In Vivo Validation

Combinatorial Therapeutics for Neurodegenerative Diseases

Powered by ReviveAI™ (SCALEX) Repurposing & DiscoveraAI™

The Neurodegenerative Disease Combinatorial Therapeutics Project aims to develop breakthrough treatments for neurodegenerative disorders such as Alzheimer's, Parkinson's, and Amyotrophic Lateral Sclerosis (ALS). By employing a combinatorial approach, researchers screen and analyze thousands of compounds simultaneously, optimizing candidates to enhance efficacy and suppress neurotoxic inflammatory cascades.

Receptor Ligand Activation & Transmembrane Cascade
CHIT1 / ALS Microglial Assay
Transmembrane Lipid Bilayer SimulationResponse: >85% Neuroinflammation Suppression
Key Experimental & Regulatory Milestones:
In vitro validation: >85% suppression of inflammatory cytokine release (TNF-alpha, IL-1beta)
TDP-43 ALS animal model: Significant protection against motor neuron axonal degeneration
Dual microglial repolarization (M1 neurotoxic to M2 neuroprotective phenotype)
Phase IIa ready repurposing protocol reducing time-to-clinic by up to 5 years
Inquire for Co-Development & In-LicensingFull Data Room available under mutual CDA
ULTR-SLEEP-11Target: GABAergic & Orexin Neuropeptide Signaling Modulation
Lead Optimization & Formulation

Novel Combinatorial Formulations for Sleep Disorders

Powered by Enformis™ & DiscoveraAI™

Ultraceuticals is at the forefront of addressing complex sleep disorders with our groundbreaking project focusing on developing combinatorial formulations. Leveraging our advanced AI-driven platform, we discover and synthesize novel compounds that offer effective, personalized solutions for sleep architecture regulation with minimal next-day sedation.

Circadian Synaptic Neurotransmitter Modulation (EEG Synchrony)
Combinatorial Lead ULTR-SLEEP-11
Dual Receptor Synaptic ModulationTarget Outcome: Slow-Wave Sleep Restoration
Key Experimental & Regulatory Milestones:
Synergistic dual-receptor binding without habituation or rebound insomnia
Optimized pharmacokinetic profile ensuring rapid onset and circadian alignment
Formulation optimized via Enformis for high oral bioavailability and shelf stability
Preclinical EEG validation demonstrating restoration of slow-wave sleep phases
Inquire for Co-Development & In-LicensingFull Data Room available under mutual CDA
ULTR-ONCO-B8Target: HER2/ER+ Kinase Crosstalk & Aromatase Axis
Preclinical Lead Synergy

Targeted Therapeutics & Formulations for Breast Health Management

Powered by DiscoveraAI™ Generative & Enformis™

The Breast Health Project focuses on targeted drug discovery and formulation management for chronic breast health conditions and oncology. Leveraging advanced AI and computational biology, we identify novel, effective drug compounds and optimize therapeutic delivery to maximize tumor suppression while reducing systemic toxicity.

Targeted Nanoparticle Extravasation & Tumor EPR Targeting
HER2/ER+ Breast Carcinoma (ULTR-ONCO-B8 Nano-Emulsion)
Enhanced Permeability & Retention (EPR) DeliveryTarget Tissue Selectivity: 3.8x Therapeutic Index
Key Experimental & Regulatory Milestones:
Sub-nanomolar selectivity against resistant oncogenic mutants over wild-type receptors
Co-crystal nano-emulsion formulation delivering 3.8x higher therapeutic index in target tissues
FTO and patent landscape fully cleared across US, European, and Indian patent offices
Demonstrated in vitro synergy with standard-of-care antineoplastic agents
Inquire for Co-Development & In-LicensingFull Data Room available under mutual CDA
ULTR-FILM-06Target: Bacterial Alginate & Pel/Psl Polysaccharide Matrix
Preclinical Lead Synergy

BioFilm Omni™: Extracellular Polymeric Substance (EPS) Matrix Disrupter

Powered by BioFilm Omni™ 6.0

Persistent bacterial biofilms represent an existential challenge in medical device implants, cystic fibrosis pulmonary infections, and non-healing wounds. BioFilm Omni 6.0 engineered ULTR-FILM-06 to selectively enzymatically cleave the polysaccharide backbone of the protective EPS matrix, resensitizing multi-drug resistant Pseudomonas aeruginosa and MRSA to conventional beta-lactams.

Enzymatic EPS Biofilm Cleavage (BioFilm Omni™ 6.0)
P. aeruginosa & MRSA Clinical Isolates
Extracellular Matrix DisruptionResensitization: 100x MBEC Reduction
Key Experimental & Regulatory Milestones:
100-fold reduction in Minimum Biofilm Eradication Concentration (MBEC)
Overcoming multi-drug antibiotic resistance in cystic fibrosis isolates
Broad-spectrum activity across both Gram-negative and Gram-positive clinical isolates
Excellent biocompatibility on human epithelial cell lines (IC50 > 500 ug/mL)
Inquire for Co-Development & In-LicensingFull Data Room available under mutual CDA